Publication: 2044

Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: Cancer and Leukemia Group B study 10002
      QxMD      Google Scholar   
Citation:
Br J Haematol vol 165 (1) 102-111
Year:
2014
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pmc-release
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
3
Parents:
474  
Children:
None
Program:
OGC
Primary Committee:
Leukemia
Sec. Committees:
   
Pharmas:
 
Grants:
U10 CA047577, U10 CA032291, CA33601, CA11789, U10 CA077658, CA77406, CA47577, CA41287, U10 CA035279, CA03927, U10 CA031946, U10 CA033601, CA59518, U10 CA180821, U10 CA059518, CA35279, U10 CA045418, CA16450, U10 CA041287, U10 CA047559, CA08025, CA74811, U10 CA180882, P30 CA016058, CA47559, CA47642, CA45418, U10 CA074811, CA77658, U10 CA180838, U10 CA047642, CA31983, CA31946, U10 CA003927  
Corr. Author:
 
Authors:
                       
Networks:
 
Study
CALGB-10002
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords:
Burkitt Leukaemia, Burkitt Lymphoma, Chemo-immunotherapy, rituximab